News | April 20, 2026
Pharma stocks face Q4 reality check amid global headwinds
Analysts expect modest revenue growth but pressure on profitability in the March quarter
Analysts expect modest revenue growth but pressure on profitability in the March quarter
Routine regulatory filing confirms completion of demat and share transfer compliances for March quarter
The India FMCG business showed a sequential recovery and is expected to post high-single digit growth
For the fourth quarter, revenue surged 47% year-on-year to Rs. 2,510 million, driven by a 23% rise in domestic sales and a 9.3x jump in export sales
Our portfolio transformation over the past few years positions us well to capitalize on improving end market conditions and deliver differentiated results in the years to come
US revenue increased 43% to $12.9 billion, fueled by a 50% jump in volume, partially offset by a 7% decline in realized prices
Operating income on consolidated basis increased by 38.10% at Rs 44.58 crore in Q4 FY25
Annual EBITDA margin expands by 170 basis points
The company reported sustained increase in formulations' share despite slowdown in productivity of Gagillapur facility
For FY25, Revenue from operation grew 28.8 per cent YoY to Rs. 70.1 crore
Subscribe To Our Newsletter & Stay Updated
